| Today’s Big NewsFeb 9, 2024 |
| By Max Bayer Roche is laying off employees within its product development team, with the total reductions slated to impact less than 6% of full-time employees in the unit. The pharma group reported 7% growth in its non-COVID business. |
|
|
|
By Nick Paul Taylor Takeda’s narcolepsy work has finally yielded a phase 2b win, albeit with a blemish. After axing one asset over liver toxicity, the Japanese drugmaker’s continued faith in the mechanism has been rewarded with a primary endpoint hit—but the midphase program only supports progression in one form of the disease. |
By James Waldron After a string of IPO success stories for clinical-stage biotechs so far this year, two companies look set to test whether they can expect the same warm reaction on the public markets this morning despite not yet having a candidate in human trials. |
Sponsored by ICON In this exclusive interview, ICON Biotech President Chris Smyth paints a picture of the operating environment facing biotechs in 2024. |
|
While individually inactive, these ingredients can cause unexpected drug interactions with the drug they are administered with and co-medications… View Symposium Recording >> 
|
|
By James Waldron Synlogic’s dreams have gone up in smoke on the news that the pivotal phase 3 study of its lead phenylketonuria drug is on track to miss its primary endpoint. |
By Max Bayer,Gabrielle Masson Well that didn’t take long! Three days after Phuong Khanh Morrow, M.D., formally departed from CRISPR Therapeutics, the ex-chief medical officer landed at Takeda as the new head of the oncology therapeutic area. |
By Helen Floersh A new discovery might offer some answers about why allergies happen—as well as open up a potential role for approved biologic drugs like Dupixent or Xolair. |
By Kevin Dunleavy CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries. |
By Andrea Park Shares of Invitae are trading for less than a nickel apiece after a report surfaced earlier this week claiming the genetic testing company is on the verge of filing for bankruptcy. |
By Ayla Ellison,Ben Adams This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
By Angus Liu Eisai said uptake of its Biogen-partnered Alzheimer's drug, Leqembi, will likely miss an early launch target. Takeda cut several cancer candidates in its latest pipeline clear-out. Roche's subcutaneous C5 inhibitor won its world-first approval in China. And more. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
